New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
NCT ID NCT07686068
First seen Jul 07, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The study has two parts: first, finding the safest dose, and then testing how well that dose works in specific cancer types.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VBC106 (a bispecific antibody drug conjugate targeting FRα and MSLN)
- What this could lead to
- If successful, VBC106 could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or may cause significant side effects. It is too early to know if it will benefit patients broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icon Cancer Centre Wesley
Brisbane, Queensland, 4066, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Houston
Houston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Mountain Region, LLC.
West Valley City, Utah, 84119, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a cancer vaccine train the body to fight advanced tumors?